Barclays set a €82.00 ($95.35) target price on Merck KGaA (FRA:MRK) in a report published on Tuesday, Borsen Zeitung reports. The brokerage currently has a sell rating on the healthcare company’s stock.

Other research analysts have also issued reports about the stock. Sanford C. Bernstein set a €105.00 ($122.09) price target on shares of Merck KGaA and gave the company a buy rating in a research note on Tuesday, February 5th. Kepler Capital Markets set a €108.00 ($125.58) price target on shares of Merck KGaA and gave the company a buy rating in a research note on Thursday, January 24th. UBS Group set a €115.00 ($133.72) price target on shares of Merck KGaA and gave the company a buy rating in a research note on Thursday, March 7th. Finally, Credit Suisse Group set a €110.00 ($127.91) target price on shares of Merck KGaA and gave the stock a buy rating in a research note on Friday, March 8th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and five have given a buy rating to the stock. Merck KGaA currently has a consensus rating of Hold and a consensus price target of €101.05 ($117.50).

Shares of Merck KGaA stock opened at €91.84 ($106.79) on Tuesday. Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Recommended Story: How interest rates affect municipal bond prices

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.